Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial1
| Autor: | Steven T. Harris, Charles Liss, Mary E. Melton, Brian W. Walsh, Christine A. Byrnes, Jane E. Reagan, Robert Lindsay, Felicia Cosman, Rogerio A. Lobo |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Bone mineral
medicine.medical_specialty Bone disease business.industry Endocrinology Diabetes and Metabolism medicine.medical_treatment Alendronic acid Biochemistry (medical) Clinical Biochemistry Osteoporosis Hormone replacement therapy (menopause) medicine.disease Placebo Biochemistry Bone remodeling Endocrinology medicine.anatomical_structure Internal medicine medicine sense organs business Femoral neck medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 84:3076-3081 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jcem.84.9.5989 |
| Popis: | Alendronate and estrogen are effective therapies for postmenopausal osteoporosis, but their efficacy and safety as combined therapy are unknown. The objective of this study was to evaluate the addition of alendronate to ongoing hormone replacement therapy (HRT) in the treatment of postmenopausal women with osteoporosis. A total of 428 postmenopausal women with osteoporosis, who had been receiving HRT for at least 1 yr, were randomized to receive either alendronate (10 mg/day) or placebo. HRT was continued in both groups. Changes in bone mineral density (BMD) and biochemical markers of bone turnover were assessed. Compared with HRT alone, at 12 months, alendronate plus HRT produced significantly greater increases in BMD of the lumbar spine (3.6% vs. 1.0%, P < 0.001) and hip trochanter (2.7% vs. 0.5%, P < 0.001); however, the between-group difference in BMD at the femoral neck was not significant (1.7% vs. 0.8%, P = 0.072). Biochemical markers of bone turnover (serum bone-specific alkaline phosphatase and u... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|